Related Experiment Video

Updated: Aug 15, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

RETMEN2A and RETMEN2B oncoproteins are targets of PP1 inhibitor

Italia Bongarzone1, Cristiana Carniti, Carla Perego

  • 1Department of Experimental Oncology, National Cancer Institute, Milan, Italy. italia.bongarzone@istitutotumori.mi.it

Tumori
|February 12, 2004
PubMed

Insights

Medullary thyroid carcinoma (MTC) is resistant to chemotherapy. PP1 inhibitor shows promise as a novel therapy by targeting RET oncoproteins, inhibiting their phosphorylation, and promoting degradation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Medullary thyroid carcinoma (MTC) exhibits poor response to conventional chemotherapy.
  • Mutations in the RET gene are a key driver in MTC development and progression.

Purpose of the Study:

  • To explore the therapeutic potential of PP1 inhibitor against RET-driven MTC.
  • To investigate the mechanism of action of PP1 inhibitor on RET oncoproteins.

Main Methods:

  • Laboratory studies investigating the effects of PP1 inhibitor on cells expressing RET oncoproteins.
  • Analysis of RET oncoprotein phosphorylation and proteasomal degradation pathways.

Main Results:

  • PP1 inhibitor demonstrated cytostatic effects on cells with RET oncoproteins.
  • PP1 inhibitor selectively inhibited RET oncoprotein phosphorylation.
  • PP1 inhibitor promoted the proteasomal degradation of RET oncoproteins.

Conclusions:

  • PP1 inhibitor represents a promising targeted therapy for MTC.
  • Targeting RET oncoproteins with PP1 inhibitor offers a novel therapeutic strategy for MTC.

More Related Videos

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...